Drug Profile
AZD 2423
Alternative Names: AZD2423Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class Anti-inflammatories; Non-opioid analgesics
- Mechanism of Action Chemokine inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Chronic obstructive pulmonary disease; Neuropathic pain
Most Recent Events
- 30 Jun 2012 Discontinued - Phase-I for Neuropathic pain in Germany (PO)
- 30 Jun 2012 Discontinued - Phase-I for Neuropathic pain in Japan (PO)
- 30 Jun 2012 Discontinued - Phase-I for Neuropathic pain in United Kingdom (PO; liquid)